- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Innoviva Inc (INVA)
The Innoviva share price today is 23.57, view NASDAQ INVA stock exchange data. Track the latest Innoviva share price with real-time updates on INVA stock performance including market cap, day range, 52-week range and dividend yield. Access INVA charts, earnings dates and analyst estimates to support your investment decisions.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
23.39
23.85
52 wk Range
16.52
25.15
Unusual trading volume
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
23.3923.85
52 wk Range
16.5225.15
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
INVA Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
35.50
Upside
+50.62%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
High shareholder yield
- Theravance receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form 8K Innoviva Inc For: 6 May
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Buy
Moving Averages
Strong Buy
Analyst Ratings
3 Buy
0 Hold
1 Sell
Ratings:
4 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 35.50
(+50.62% Upside)
Earnings
Latest Release
06-05-2026
EPS / Forecast
2.22 / 0.40
Revenue / Forecast
97.99M / 101.56M
Compare INVA to Peers and Sector
Metrics to compare | INVA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipINVAPeersSector | |
|---|---|---|---|---|
P/E Ratio | 3.4x | 4.1x | −0.4x | |
PEG Ratio | 0.00 | 0.05 | 0.00 | |
Price/Book | 1.3x | 1.4x | 2.6x | |
Price / LTM Sales | 4.1x | 2.4x | 3.0x | |
Upside (Analyst Target) | 67.1% | 410.0% | 56.2% | |
Fair Value Upside | Unlock | 17.7% | 8.9% | Unlock |
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter; XERAVA for the treatment of complicated intra-abdominal infections in adults; ZEVTERA an advanced-generation cephalosporin antibiotic for the treatment of staphylococcus aureus bacteremia, as well as with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia; NUZOLVENCE for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents. In addition, the company develops bacteriophages with potential use in a range of infectious and other serious diseases. It has a strategic partnership with Sarissa Capital Management LP; and LABA Collaboration Agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Innoviva (INVA) Share Price Today?
The Innoviva share price today is 23.57.
What is the current Innoviva (INVA) share price and day range?
As of 26-06-2026, the Innoviva share price is 23.57, with a previous close of 23.35. The share price has ranged from 23.39 to 23.85 today, while the 52-week range spans from 16.52 to 25.15.
What Is the Innoviva Market Cap?
As of today, Innoviva market cap is 1.73B.
What Is the Innoviva (INVA) Share Price Target?
The average 12-month share price target for Innoviva is 35.50, with a high estimate of 46 and a low estimate of 18. 3 analysts recommend buying, while 1 suggest selling, with an overall rating of Buy and +50.62% Upside potential.
What Is Innoviva's Earnings Per Share (TTM)?
The Innoviva EPS (TTM) is 5.69.
When Is the Next Innoviva Earnings Date?
Innoviva will release its next earnings report on 29-07-2026.
From a Technical Analysis Perspective, Is INVA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does Innoviva Trade On?
Innoviva is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Innoviva?
The stock symbol for Innoviva is "INVA."
How Many Times Has Innoviva Stock Split?
Innoviva has split 0 times.
How Many Employees Does Innoviva Have?
Innoviva has 159 employees.
What Is the INVA Premarket Price?
INVA's last pre-market stock price is 23.30. The pre-market share volume is 1,540.00, and the stock has changed by -0.05, or -0.21%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.